| 1 |
Abp 959 - biosimilar to eculizumab |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 [1] 62 💬 |
| 2 |
Abp 959 - proposed biosimilar to eculizumab |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 [1] 62 💬 |
| 3 |
Eculizumab |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
011 [8] 11, 13, 14, 61, 62, 109, 222, 223 💬 |
| 4 |
Other: blood collection for measurement of eculizumab peak concentrations |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 [1] 62 💬 |
| 5 |
Other: eculizumab |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
109 [1] 109 💬 |
| 6 |
Sb12 (proposed eculizumab biosimilar) |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 [1] 62 💬 |
| 7 |
Soliris |
- |
- |
- |
- |
011 [7] 11, 13, 14, 61, 62, 109, 222 💬 |
| 8 |
Soliris (eculizumab) |
Eculizumab |
[1] D03940 D03940 💬 |
C5 [1] C5 💬 |
Complement and coagulation cascades [9] Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 [1] 62 💬 |
| 9 |
Soliris (r) |
- |
- |
- |
- |
061 [1] 61 💬 |
| 10 |
Soliris - 300 mg concentrato per soluzione per infusione - uso endovenoso 1 flaconcino (vetro) 30 ml (10 mg/ml) |
- |
- |
- |
- |
109 [1] 109 💬 |
| 11 |
Soliris 300 |
- |
- |
- |
- |
062 [1] 62 💬 |
| 12 |
Soliris 300 mg concentrado para solución para perfusión |
- |
- |
- |
- |
109 [1] 109 💬 |
| 13 |
Soliris® |
- |
- |
- |
- |
062 [1] 62 💬 |